NEXSTAR PHARMACEUTICALS INC
424B5, 1997-11-26
PHARMACEUTICAL PREPARATIONS
Previous: TELULAR CORP, PRE 14A, 1997-11-26
Next: STRATASYS INC, SC 13D, 1997-11-26



<PAGE>
                                                
                                                Filed Pursuant to Rule 424(b)(3)
                                                      Registration No. 333-35827

                    SUPPLEMENT NO. 1 DATED NOVEMBER 26, 1997
                       TO PROSPECTUS DATED OCTOBER 6, 1997
                                   RELATING TO
        $80,000,000 6 1/4% CONVERTIBLE SUBORDINATED DEBENTURES DUE 2004
                    INTEREST PAYABLE FEBRUARY 1 AND AUGUST 1
           AND SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION THEREOF

     All  capitalized  terms used but not defined herein shall have the meanings
set forth in the Prospectus dated October 6, 1997 (the "Prospectus"),  forming a
part of the Registration Statement on Form S-3 (Registration No. 333-35827). Any
cross references in this Supplement refer to portions of the Prospectus.

     The  purpose  of  this  Supplement  is to  provide  additional  information
regarding   the   Selling   Securityholders.   In   addition   to  the   Selling
Securityholders named in the Prospectus, the following table sets forth the name
of each additional  Selling  Securityholder  and relationship,  if any, with the
Company  and (i) the  amount  of  Debentures  owned by each  additional  Selling
Securityholder  as of November 21, 1997 (subject to the  qualification set forth
below),  (ii) the  maximum  amount of  Debentures  which may be offered  for the
account of such additional Selling  Securityholder  under the Prospectus,  (iii)
the amount of Common Stock owned by each additional Selling Securityholder as of
November  21,  1997,  and (iv) the maximum  amount of Common  Stock which may be
offered for the account of such Selling Securityholder under the Prospectus.
<TABLE>
<CAPTION>


                                                                              Shares of Common
                                Principal Amount      Principal Amount of     Stock Owned         Shares of Common
                                of Debentures Owned   Debentures   Offered    Prior to Offering   Stock Offered Hereby
Name of Selling Securityholder                        Hereby                  (1)                 (2)
- ------------------------------                        ------                  ---                 ---
<S>                               <C>                    <C>                     <C>                   <C>    

SBC  Warburg  Dillon Read Inc.    $11,593,000             $11,593,000             686,993              686,993
   (3).......................
Highbridge             Capital     3,500,000              3,500,000               207,407              207,407
   Corporation. .............
Oppenheimer Bond Fund for
   Growth ...................      3,500,000              3,500,000               207,407              207,407
BNP Arbitrage SNC............      2,000,000              2,000,000               125,519              118,519
Swiss Bank Corporation  London
   Branch (4)................      1,300,000              1,300,000                77,037               77,037
                                
Merrill  Lynch Pierce Fenner &
   Smith Inc. ...............        750,000                750,000                44,444               44,444
Salamon Brothers Execution...        750,000                750,000                44,444               44,444
Southport             Partners
   International  L.P........        750,000                750,000                44,444               44,444
Southport  Management Partners       
   L.P.......................        750,000                750,000                44,444               44,444
Offshore Strategies Ltd. ....        650,000                650,000                38,519               38,519
Laterman Strategies 90's LLC.        240,000                240,000                14,222               14,222
Laterman & Co. ..............        110,000                110,000                 6,519                6,519
                                     -------                -------                 -----                -----

Total........................     $25,893,000             $25,893,000                 N/A            1,534,399
                                  ===========             ============                ===            =========
</TABLE>

- -----------------------
(1)  Includes the shares of Common Stock into which the Debentures  held by such
     Selling Securityholder are convertible at the initial conversion price. The
     conversion  price and the number of shares of Common  Stock  issuable  upon
     conversion  of the  Debentures  are  subject to  adjustment  under  certain
     circumstances.   See  "Description  of  Debentures  -  Conversion  Rights."
     Accordingly,  the number of shares of Common Stock issuable upon conversion
     of the Debentures may increase or decrease from time to time.
(2)  Assumes  conversion into Common Stock of the full amount of Debentures held
     by  such  Selling  Securityholder  at the  initial  conversion  price.  The
     conversion  price and the number of shares of Common  Stock  issuable  upon
     conversion  of the  Debentures  are  subject to  adjustment  under  certain
     circumstances.   See  "Description  of  Debentures  -  Conversion  Rights."
     Accordingly,  the number of shares of Common Stock issuable upon conversion
     of the  Debentures  may increase or decrease from time to time.  Fractional
     shares will not be issued upon conversion of the Debentures;  rather,  cash
     will be paid in lieu of fractional shares, if any.


<PAGE>


(3)  SBC Warburg Dillon Read Inc.  (formerly SBC Warburg Inc.) and Oppenheimer &
     Co., Inc. were Initial  Purchasers of the Company's  $80,000,000  aggregate
     principal  amount of Debentures.  The sale of the Debentures by the Company
     to the  Initial  Purchasers  was  made  pursuant  to  Section  4(2)  of the
     Securities  Act of 1933.  The Initial  Purchasers  resold the Debentures in
     reliance  on Rule 144A under the  Securities  Act of 1933 and  outside  the
     United States to certain  persons in offshore  transactions  in reliance on
     Regulation  S under the  Securities  Act of 1933.  The  Initial  Purchasers
     received discounts and commissions in connection with the initial placement
     of the Debentures of $2,400,000. The Debentures set forth opposite the name
     of SBC Warburg  Dillon  Read Inc.  represent  securities  held by it in its
     market making capacity.
(4)  SBC Warburg  Dillon  Read Inc.  acts as  investment  adviser for Swiss Bank
     Corporation London Branch. See Note (3) above.

     Because the Selling Securityholders may, pursuant to this Prospectus, offer
all or some portion of the  Debentures  and Common Stock they presently hold or,
with respect to Common Stock,  have the right to acquire upon conversion of such
Debentures,  no  estimate  can be given as to the amount of the  Debentures  and
Common Stock that will be held by the Selling  Securityholders  upon termination
of any such sales. In addition, the Selling Securityholders identified above may
have  sold,  transferred  or  otherwise  disposed  of all or a portion  of their
Debentures  and  Common  Stock  since  the  date  on  which  they  provided  the
information  regarding their Debentures and Common Stock, in transactions exempt
from the  registration  requirements of the Securities Act of 1933. See "Plan of
Distribution."

     The  Company may from time to time,  in  accordance  with the  Registration
Rights  Agreement,   include  additional   Selling   Securityholders  in  future
supplements to the Prospectus.

     Except as described above, none of the Selling Securityholders listed above
had any  material  relationship  with the  Company  other  than as a  result  of
ownership of the Debentures,  within the three-year period ending on the date of
this Prospectus.




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission